Abstract:A comprehensive summary of recent advances in SARS‐CoV‐2 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives), including the inhibitory activities, inhibitory mechanisms, and key structural features, provides new insights for designing and developing more efficacious 3CLpro inhibitors as broad‐spectrum anti‐coronavirus agents. The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease Mpro (also known as 3CLpro), as well as recent advances in discovering and developing SARS‐CoV‐2 3CLpro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CLpro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CLpro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CLpro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CLpro inhibitors as novel anti‐coronavirus agents.

An overview of potential inhibitors targeting non-structural proteins 3 (PL<SUP>pro</SUP> and Mac1) and 5 (3CL<SUP>p</SUP><SUP>ro</SUP>/M<SUP>pro</SUP>) of SARS-CoV-2

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Targeting SARS-CoV-2 Nonstructural Protein 3: Function, Structure, Inhibition, and Perspective in Drug Discovery

Potential of Coronavirus 3C-Like Protease Inhibitors for the Development of New Anti-Sars-cov-2 Drugs: Insights from Structures of Protease and Inhibitors.

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Potential Therapeutic Approaches for the Early Entry of SARS-CoV-2 by Interrupting the Interaction Between the Spike Protein on SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2)

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M<SUP>pro</SUP>

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Structures of SARS-CoV-2 RNA-Binding Proteins and Therapeutic Targets

Potential Inhibitors for Targeting Mpro and Spike of SARS-CoV-2 Based on Sequence and Structural Pharmacology Analysis

Progress on SARS-CoV-2 3clpro Inhibitors: Inspiration from SARS-CoV 3clpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease

Advances in Enzymatic Activity Regulation Mechanism and Inhibitor Discovery of Coronavirus 3C-Like Protease

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.

3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources